- Home
- GILD vs C Comparison
GILD vs C Comparison
Compare GILD & C Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | C |
|---|---|---|
| Founded | 1987 | 1812 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 193.7B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | C |
|---|---|---|
| Price | $128.48 | $128.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 16 |
| Target Price | ★ $148.39 | $134.81 |
| AVG Volume (30 Days) | 4.4M | ★ 8.6M |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.52% | 1.88% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.68 | $24.26 |
| Revenue Next Year | $6.04 | $3.63 |
| P/E Ratio | $19.22 | ★ $16.63 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $66.72 |
| 52 Week High | $157.29 | $135.29 |
Technical Indicators
Market Signals| Indicator | GILD | C |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 61.57 |
| Support Level | $116.55 | $108.46 |
| Resistance Level | $142.33 | N/A |
| Average True Range (ATR) | 2.99 | 2.83 |
| MACD | -0.89 | -0.14 |
| Stochastic Oscillator | 1.09 | 48.23 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 160 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.